Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Consolidated Statements of Operations
Net Revenues	$ 206,547	$ 201,576	$ 176,842
Operating Expenses
Cost of sales (excluding depreciation and amortization)	63,154	73,024	79,032
Research and development	19,806	15,388	9,070
Selling, general, and administrative	55,843	44,063	31,580
Depreciation and amortization	44,612	33,742	27,928
Cortrophin pre-launch charges	6,706	0	0
Intangible asset impairment charge	75	0	903
Total Operating Expenses	190,196	166,217	148,513
Operating Income	16,351	35,359	28,329
Other Expense, net
Interest expense, net	(12,966)	(14,758)	(12,035)
Other (expense)/income, net	(228)	(550)	55
Income Before Benefit/(Provision) for Income Taxes	3,157	20,051	16,349
Benefit/(provision) for income taxes	2,937	(4,557)	(17,425)
Net Income	$ 6,094	$ 15,494	$ (1,076)
Basic and Diluted Earnings/(Loss) Per Share:
Basic Earnings/(Loss) Per Share	$ 0.51	$ 1.31	$ (0.09)
Diluted Earnings/(Loss) Per Share	$ 0.50	$ 1.30	$ (0.09)
Basic Weighted-Average Shares Outstanding	11,841	11,677	11,547
Diluted Weighted-Average Shares Outstanding	12,040	11,772	11,547